Milestone Pharmaceuticals (MIST) Receivables - Other (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Receivables - Other came in at $1.2 million in Q1 2026, up 1.97% YoY from $1.2 million in Q1 2025, and up 25.79% on a QoQ basis from $946000.0 in Q4 2025.
Milestone Pharmaceuticals (MIST) Receivables - Other (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Receivables - Other data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Receivables - Other rose 1.97% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 1.97% YoY) and the FY2025 annual result came in at $1.6 million, up 195.81% from the prior year.
- Receivables - Other climbed to $1.2 million in Q1 2026, from $946000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $1.7 million in Q4 2023 to a low of -$1.8 million in Q1 2024.
- A 5-year average of $668058.8 and a median of $694000.0 in 2023 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2022 — Receivables - Other soared 1076.32% — and 2024, when it sank 358.65%.
- Tracing MIST's Receivables - Other over 5 years: stood at $447000.0 in 2022, then surged by 277.4% to $1.7 million in 2023, then sank by 83.46% to $279000.0 in 2024, then jumped by 239.07% to $946000.0 in 2025, then gained by 25.79% to $1.2 million in 2026.
- The last three Receivables - Other figures came in at $1.2 million (Q1 2026), $946000.0 (Q4 2025), and $398000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 726,000.00 |
| Jun 30, 2026 | 726,000.00 |
| Mar 31, 2026 | 1.19 Mn |
| Mar 31, 2026 | 1.19 Mn |
| Dec 31, 2025 | 946,000.00 |
| Dec 31, 2025 | 946,000.00 |
| Sep 30, 2025 | 398,000.00 |
| Sep 30, 2025 | 398,000.00 |
| Jun 30, 2025 | 113,000.00 |
| Jun 30, 2025 | 113,000.00 |
| Mar 31, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 279,000.00 |
| Dec 31, 2024 | 279,000.00 |
| Sep 30, 2024 | 1.06 Mn |
| Sep 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | 1.62 Mn |
| Jun 30, 2024 | 1.62 Mn |
| Mar 31, 2024 | -1.80 Mn |
| Mar 31, 2024 | -1.80 Mn |